Residency · Residency · Geriatrics

Dementia - Alzheimer Disease Evaluation and Management

Introduction

Alzheimer disease is the most common cause of dementia, accounting for 60 to 80 percent of all cases and representing one of the most significant public health challenges of the twenty-first century. As of 2024, approximately 6.9 million Americans aged 65 and older are living with Alzheimer disease, a number projected to reach 12.7 million by 2050 as the population ages. The prevalence of Alzheimer disease doubles with every five-year increment of age after 65, affecting roughly 5 percent of individuals at age 65 and approximately 30 percent of those aged 85 and older. It is the sixth leading cause of death in the United States overall and the third leading cause of death among elderly adults, trailing only heart disease and cancer.

The economic burden of Alzheimer disease is staggering. Annual costs in the United States reached 360 billion dollars in 2024, with unpaid caregiving by family members and friends valued at an additional 350 billion dollars. These figures capture only the direct and quantifiable costs; they do not account for the immeasurable toll of suffering experienced by patients and their families as they navigate a progressive, ultimately fatal disease that strips away identity, autonomy, and connection.

A fundamental conceptual shift has occurred in the understanding of Alzheimer disease over the past two decades. The disease is now recognized as a biological continuum rather than a discrete clinical entity. This continuum begins with a preclinical phase in which individuals harbor pathological biomarkers (amyloid and tau deposition) but remain cognitively normal, progresses through mild cognitive impairment due to Alzheimer disease in which cognitive deficits are measurable but functional independence is preserved, and culminates in Alzheimer disease dementia in which cognitive decline is severe enough to impair daily functioning. This reconceptualization has profound implications for diagnosis, treatment eligibility, and the timing of therapeutic intervention.

Pathophysiology

Amyloid Cascade Hypothesis

The amyloid cascade hypothesis has dominated Alzheimer disease research for over three decades and posits that the accumulation of amyloid-beta peptide is the initiating event in the disease process. Amyloid-beta is generated through the sequential cleavage of amyloid precursor protein by beta-secretase (BACE1) followed by gamma-secretase. This amyloidogenic processing pathway produces amyloid-beta peptides of varying lengths, of which amyloid-beta 42 is the most amyloidogenic and neurotoxic species. Amyloid-beta 42 has a strong propensity to aggregate, forming progressively larger assemblies: monomers aggregate into soluble oligomers, which assemble into protofibrils, which ultimately deposit as insoluble amyloid plaques in the brain parenchyma.

Current evidence indicates that soluble amyloid-beta oligomers, rather than the insoluble plaques themselves, are the primary neurotoxic species. These oligomers disrupt synaptic function, impair long-term potentiation, and trigger downstream pathological cascades well before plaque formation becomes evident on neuroimaging. This understanding explains a longstanding paradox in Alzheimer disease research: amyloid plaques are necessary but not sufficient for the development of clinical dementia. Many cognitively normal elderly individuals harbor significant amyloid burden at autopsy, indicating that additional pathological processes must be engaged for clinical disease to manifest.

Tau Pathology

Tau is a microtubule-associated protein that normally stabilizes the neuronal cytoskeleton. In Alzheimer disease, tau becomes hyperphosphorylated at multiple sites, causing it to dissociate from microtubules and aggregate into neurofibrillary tangles. The density and distribution of neurofibrillary tangles correlate more closely with the severity of cognitive decline than does amyloid burden, making tau pathology a more direct marker of neurodegenerative progression.

The spread of tau pathology follows a stereotyped anatomical pattern described by the Braak staging system.

In stages I and II, neurofibrillary tangles are confined to the transentorhinal cortex, corresponding to the preclinical phase of disease. Stages III and IV involve the limbic structures, including the hippocampus and entorhinal cortex, and correspond to the mild cognitive impairment phase. Stages V and VI reflect neocortical involvement, corresponding to established dementia. Tau propagation follows a prion-like mechanism, spreading trans-synaptically along connected neuronal networks, which explains both the stereotyped anatomical progression and the correlation between tau distribution and the specific cognitive deficits observed at each stage.

Other Mechanisms

Neuroinflammation plays an increasingly recognized role in Alzheimer disease pathogenesis. Microglial activation, initially a protective response aimed at clearing amyloid deposits, becomes chronically dysregulated and contributes to neuronal damage. Variants in the TREM2 gene, which encodes a microglial receptor involved in phagocytosis and inflammatory regulation, confer a two- to four-fold increased risk of Alzheimer disease, underscoring the importance of innate immune function in disease susceptibility. Astrocyte reactivity further amplifies the neuroinflammatory cascade.

Synaptic loss is the strongest neuropathological correlate of cognitive decline in Alzheimer disease, exceeding the correlation with either amyloid plaques or neurofibrillary tangles. Synaptic dysfunction and loss precede neuronal death, and the degree of synaptic depletion in specific cortical regions maps closely onto the specific cognitive deficits observed clinically. The cholinergic deficit resulting from degeneration of the nucleus basalis of Meynert, a major source of cortical cholinergic innervation, provides the pathophysiological basis for cholinesterase inhibitor therapy.

Cerebrovascular disease contributes significantly to cognitive impairment in Alzheimer disease. Mixed pathology combining Alzheimer disease and vascular changes is the most common finding at autopsy in demented elderly individuals, and the synergistic interaction between amyloid and vascular pathology accelerates cognitive decline beyond what either process would produce alone.

The apolipoprotein E epsilon 4 allele (APOE4) is the strongest genetic risk factor for sporadic Alzheimer disease. APOE4 heterozygotes carry approximately three-fold increased risk while homozygotes carry twelve-fold increased risk. APOE4 influences multiple pathological pathways, including amyloid-beta clearance and aggregation, tau phosphorylation, neuroinflammation, and cerebrovascular integrity, explaining its powerful effect on disease risk.

<image>A detailed cross-sectional diagram of Alzheimer disease neuropathology. Show a comparison between a normal neuron and an AD-affected neuron. The normal neuron should have intact microtubules with properly bound tau protein, clear synaptic connections, and healthy mitochondria. The AD-affected neuron should show: extracellular amyloid-beta plaques with activated microglia and reactive astrocytes surrounding them; intracellular neurofibrillary tangles made of hyperphosphorylated tau; disrupted microtubules; dystrophic neurites; synaptic loss; and mitochondrial dysfunction. Include a small inset showing the APP processing pathway with alpha-secretase (non-amyloidogenic) vs. beta/gamma-secretase (amyloidogenic) cleavage. Label all components clearly with molecular details.</image>

Clinical Evaluation

History and Symptom Assessment

The clinical presentation of Alzheimer disease is characterized by insidious onset and gradually progressive cognitive decline unfolding over months to years. An informant history obtained from a spouse, family member, or close friend is essential because patients frequently underreport or minimize their symptoms due to anosognosia, the lack of insight into one's own cognitive deficits that is itself a hallmark of the disease. Relying solely on patient self-report will miss or underestimate the severity of cognitive impairment in the majority of cases.

The typical presenting symptom is impairment of episodic memory, specifically the inability to learn and retain new information. Patients ask repetitive questions, misplace objects, forget appointments and recent conversations, and lose track of events that occurred days or even hours earlier. This memory deficit follows a temporal gradient in which recent memories are affected first while remote autobiographical memories remain relatively preserved early in the disease course, reflecting the initial vulnerability of hippocampal and medial temporal lobe structures.

Language difficulties emerge as the disease progresses, beginning with word-finding difficulty (anomia) and advancing to fluent aphasia with progressively empty speech, impaired comprehension, and eventual mutism. Visuospatial dysfunction manifests as getting lost in familiar environments, difficulty navigating, and impaired ability to copy or construct complex figures. Executive dysfunction includes impaired judgment, loss of planning and organizational abilities, and difficulty with financial management, which is often the first instrumental activity of daily living to deteriorate.

Behavioral and neuropsychiatric symptoms are nearly universal at some point during the disease course. Apathy is the most common neuropsychiatric symptom, affecting 50 to 70 percent of patients, and is frequently mistaken for depression. Depression, anxiety, and irritability are also common. Importantly, atypical presentations are recognized, particularly in younger-onset Alzheimer disease (onset before age 65). Posterior cortical atrophy, the visual variant, presents with prominent visuospatial and visuoperceptual deficits with relatively preserved memory. The logopenic variant of primary progressive aphasia is characterized by word-finding pauses, phonological errors, and impaired sentence repetition. The frontal or dysexecutive variant presents with behavioral changes and executive dysfunction that may initially mimic frontotemporal dementia.

Cognitive Testing

Brief cognitive screening instruments provide the initial objective assessment of cognitive function. The Montreal Cognitive Assessment (MoCA) is preferred over the Mini-Mental State Examination (MMSE) for detecting mild cognitive impairment, with a cutoff of 25 or below indicating abnormality and a reported sensitivity of approximately 90 percent for MCI. The Mini-Cog, combining three-item recall with clock drawing, offers an efficient bedside screen that can be completed in approximately three minutes.

Formal neuropsychological testing represents the gold standard for characterizing the cognitive profile and is particularly valuable when the diagnosis is uncertain, atypical presentations are suspected, or precise staging is needed. A comprehensive battery tests multiple cognitive domains including memory (Auditory Verbal Learning Test, California Verbal Learning Test), attention, executive function (Trail Making Test Part B, Wisconsin Card Sorting Test), language (Boston Naming Test), and visuospatial abilities (Rey Complex Figure Test). In Alzheimer disease, neuropsychological testing characteristically reveals a prominent amnestic deficit with temporal gradient, and the pattern of deficits helps distinguish Alzheimer disease from other dementia etiologies. Neuropsychological testing also distinguishes MCI from dementia based on the extent of functional impact.

Staging of disease severity employs standardized instruments. The Clinical Dementia Rating (CDR) scale assigns scores of 0 (normal), 0.5 (MCI or questionable dementia), 1 (mild dementia), 2 (moderate dementia), or 3 (severe dementia) based on assessment of six domains. The MMSE provides rough staging guidance, with scores of 21 to 26 indicating mild dementia, 10 to 20 indicating moderate dementia, and below 10 indicating severe dementia, though floor and ceiling effects significantly limit its utility at the extremes.

Diagnostic Workup

The laboratory workup for suspected Alzheimer disease is directed primarily at excluding reversible causes of cognitive impairment. Standard studies include a complete blood count, comprehensive metabolic panel, thyroid-stimulating hormone, vitamin B12, and folate. Additional studies such as RPR or VDRL, HIV testing, heavy metal screening, and autoimmune encephalitis antibodies should be considered based on clinical risk factors, particularly when the onset is rapid or the presentation atypical.

Structural neuroimaging with MRI of the brain without contrast is the preferred imaging modality. The characteristic Alzheimer disease pattern includes medial temporal lobe atrophy with hippocampal volume loss and posterior parietal atrophy. Structural imaging also serves to exclude alternative diagnoses such as subdural hematoma, brain tumor, and normal pressure hydrocephalus. Visual rating scales such as the Medial Temporal Atrophy (MTA) scale developed by Scheltens provide semiquantitative assessment, with a grade of 2 or greater considered abnormal for patients under age 75.

The biomarker framework for Alzheimer disease has been transformed by the NIA-AA 2018 AT(N) classification, which categorizes biomarkers according to the pathological process they measure. Amyloid (A) biomarkers include cerebrospinal fluid amyloid-beta 42 (decreased in Alzheimer disease), the amyloid-beta 42/40 ratio (decreased), and amyloid PET imaging using tracers such as florbetapir, flutemetamol, or florbetaben (positive signal indicating amyloid deposition). Tau (T) biomarkers include cerebrospinal fluid phosphorylated tau at positions 181 and 217 (elevated) and tau PET imaging with flortaucipir (positive signal). Neurodegeneration (N) biomarkers include cerebrospinal fluid total tau (elevated), FDG-PET showing temporoparietal hypometabolism, and structural MRI demonstrating atrophy.

Blood-based biomarkers are rapidly emerging into clinical practice and represent a transformative advance in Alzheimer disease diagnostics. Plasma phosphorylated tau 217 (p-tau217) achieves an area under the curve of 0.96 for predicting amyloid PET positivity, as demonstrated by Palmqvist and colleagues in 2020. The commercially available PrecivityAD2 blood test measures both p-tau217 and the amyloid-beta 42/40 ratio, providing a minimally invasive means of confirming Alzheimer disease pathology without the need for PET imaging or lumbar puncture.

Genetic testing is not performed routinely but should be considered in patients with onset before age 65, those with a strong family history of early-onset dementia, or at patient request. Deterministic autosomal dominant mutations in APP, PSEN1, and PSEN2 account for less than 1 percent of all Alzheimer disease cases. APOE genotyping, which identifies the risk allele epsilon 4, remains controversial in clinical practice but is increasingly relevant for guiding eligibility and risk stratification for anti-amyloid therapies.

Diagnostic Criteria

NIA-AA 2018 Research Framework (AT(N))

The 2018 NIA-AA Research Framework represents a paradigm shift in Alzheimer disease diagnosis, defining the disease biologically by its biomarker profile rather than clinically by its symptoms. Under this framework, the designation A-positive, T-positive (A+T+) defines Alzheimer disease pathological change regardless of whether the individual is symptomatic. The addition of neurodegeneration markers (A+T+N+) indicates Alzheimer disease with evidence of active neurodegeneration. This biological definition enables identification of individuals at the earliest preclinical stages, long before the onset of cognitive symptoms, and provides the conceptual foundation for preventive and early interventional trials.

Clinical Diagnosis (Practical Approach)

In clinical practice, the diagnosis of probable Alzheimer disease dementia is made when there is an insidious onset and gradually progressive cognitive decline in an amnestic pattern, with no other explanation for the deficits, and ideally with biomarker support if available. Possible Alzheimer disease dementia is diagnosed when the clinical course is atypical or when there is evidence of a mixed etiology. Mild cognitive impairment due to Alzheimer disease is diagnosed when there is a subjective cognitive complaint corroborated by objective cognitive impairment on testing, functional independence is preserved, and biomarker evidence supports underlying Alzheimer disease pathology.

<image>A diagnostic algorithm flowchart for evaluating suspected Alzheimer disease. Start with "Cognitive complaint (patient or informant)" leading to initial cognitive screening (MoCA or Mini-Cog). If abnormal, proceed to history (insidious onset, progressive), functional assessment (ADL/IADL impact determines MCI vs dementia), laboratory workup (TSH, B12, CMP, CBC), and brain MRI. Then show decision points: if typical amnestic presentation with medial temporal atrophy, proceed to "Probable AD" with optional biomarker confirmation. If atypical features or diagnostic uncertainty, proceed to biomarker evaluation: blood-based biomarkers (p-tau217) as initial screen, then CSF or amyloid PET for confirmation if needed. Show separate pathways for young-onset (<65) requiring genetic counseling and expanded workup. Include a side panel showing the AT(N) classification grid with all possible biomarker combinations and their interpretations.</image>

Management

Cholinesterase Inhibitors

Cholinesterase inhibitors remain the cornerstone of symptomatic therapy for Alzheimer disease, targeting the cholinergic deficit that results from degeneration of the nucleus basalis of Meynert. Three agents are available, each with distinct pharmacological properties and clinical considerations.

Donepezil is a reversible acetylcholinesterase inhibitor with a long half-life of approximately 70 hours, permitting once-daily dosing. It is initiated at 5 mg daily for four weeks and then increased to 10 mg daily. A 23 mg formulation is available for moderate-to-severe disease. Donepezil is approved for mild, moderate, and severe Alzheimer disease. Common side effects include nausea (11 percent), diarrhea (10 percent), insomnia, vivid dreams, and bradycardia.

Rivastigmine is a dual inhibitor of both acetylcholinesterase and butyrylcholinesterase. The transdermal patch formulation is preferred over oral dosing due to significantly fewer gastrointestinal side effects (7 percent nausea with the patch versus 29 percent with oral administration). Patch dosing is initiated at 4.6 mg per 24 hours and titrated to 9.5 mg per 24 hours and then to 13.3 mg per 24 hours. Rivastigmine is approved for mild-to-moderate Alzheimer disease and is the only cholinesterase inhibitor also approved for Parkinson disease dementia.

Galantamine combines acetylcholinesterase inhibition with allosteric modulation of nicotinic receptors. It is dosed at 4 mg twice daily, titrated to 8 mg twice daily, and then to 12 mg twice daily, with an extended-release formulation available for once-daily dosing. Galantamine is approved for mild-to-moderate Alzheimer disease.

The efficacy of cholinesterase inhibitors is modest in absolute terms, with a typical improvement of 1.5 to 3 points on the MMSE over six months compared to placebo, along with a delay in functional decline. Their clinical significance is best understood as stabilization rather than improvement, and their benefit is most apparent when the medication is discontinued and the rate of cognitive decline accelerates. Cholinesterase inhibitors carry important cautions including the risk of bradycardia (they should be avoided in patients with heart block or sick sinus syndrome), syncope, exacerbation of peptic ulcer disease, worsening of obstructive pulmonary disease, and urinary obstruction.

NMDA Receptor Antagonist

Memantine is an uncompetitive NMDA receptor antagonist that blocks excessive glutamate signaling, which contributes to excitotoxicity and neuronal death in Alzheimer disease. It is initiated at 5 mg daily and titrated in weekly 5 mg increments to a target of 10 mg twice daily. An extended-release formulation is available, titrated from 7 mg to 28 mg daily. Memantine is approved for moderate-to-severe Alzheimer disease.

The combination of memantine with a cholinesterase inhibitor (typically donepezil) provides additive benefit. The DOMINO-AD trial demonstrated that the combination was superior to monotherapy with either agent alone, establishing combination therapy as the standard approach for moderate-to-severe disease. Memantine is generally well tolerated, with dizziness, headache, and confusion being the most commonly reported side effects.

Anti-Amyloid Monoclonal Antibodies

The approval of anti-amyloid monoclonal antibodies represents the most significant therapeutic advance in Alzheimer disease in decades, offering the first disease-modifying treatments that target the underlying pathology rather than merely managing symptoms.

Lecanemab is a humanized monoclonal antibody that selectively binds soluble amyloid-beta protofibrils, the species considered most neurotoxic. The CLARITY AD trial, published in 2023, demonstrated a 27 percent slowing of cognitive decline as measured by the CDR-SB over 18 months compared to placebo, with a 59 percent reduction in amyloid PET signal. Lecanemab is administered as an intravenous infusion of 10 mg per kilogram every two weeks, with a subcutaneous formulation approved in 2025. The principal safety concern is amyloid-related imaging abnormalities (ARIA), with ARIA-E (edema) occurring in 12.6 percent and ARIA-H (hemorrhage) in 17.3 percent of treated patients, though most cases are asymptomatic. APOE4 homozygotes face substantially higher ARIA risk (35.4 percent ARIA-E), necessitating careful risk-benefit discussion. Treatment requires confirmed amyloid positivity by PET or CSF, a baseline MRI, and serial MRI monitoring at minimum at weeks 5, 7, and 14 during the first year.

Donanemab is a monoclonal antibody that targets N-terminal pyroglutamate amyloid-beta, a modified form found specifically in deposited amyloid plaques. The TRAILBLAZER-ALZ 2 trial, published in 2023, demonstrated a 35 percent slowing of cognitive decline in the combined tau population and a 40 percent slowing in the low-to-medium tau subgroup. A unique feature of donanemab is its time-limited dosing strategy: treatment is discontinued once amyloid clearance is achieved, with 47 percent of participants completing treatment by 12 months. Dosing begins at 700 mg intravenously every four weeks for three doses, then increases to 1400 mg every four weeks. ARIA rates are higher than with lecanemab (ARIA-E 24 percent, ARIA-H 31.4 percent), and three treatment-related deaths (0.4 percent) were reported. Donanemab received FDA approval in 2024 for early symptomatic Alzheimer disease with confirmed amyloid.

Aducanumab was withdrawn from the market in 2024 following controversy surrounding its accelerated approval based on biomarker endpoints (amyloid reduction) rather than demonstrated clinical benefit.

Eligibility for anti-amyloid therapy is limited to patients with early symptomatic Alzheimer disease (MCI or mild dementia stage), confirmed amyloid pathology, and absence of significant cerebrovascular disease or anticoagulation use, which are relative contraindications due to increased ARIA risk.

Non-Pharmacological Management

Non-pharmacological interventions are essential components of comprehensive Alzheimer disease management and address domains that pharmacotherapy cannot. Cognitive stimulation therapy, a group-based structured program, has demonstrated cognitive and quality-of-life benefits in a Cochrane review, with a standardized mean difference of 0.44 on cognition measures. Physical exercise at a target of 150 minutes per week of moderate aerobic activity combined with resistance training shows modest cognitive benefit and reduces behavioral and psychological symptoms of dementia in meta-analyses. Music therapy, particularly with personalized music programs, reduces agitation and anxiety. Occupational therapy incorporating home modifications, compensatory strategies, and caregiver training, as exemplified by the COTID (Community Occupational Therapy in Dementia) program, supports functional independence.

Caregiver support is a critical and often underemphasized aspect of Alzheimer disease management. Caregiver health directly predicts patient outcomes, and caregiver burnout accelerates institutionalization. The NYU Caregiver Intervention developed by Mittelman demonstrated that a program of individual counseling combined with support group participation delayed nursing home placement by 1.5 years. Resources including the Alzheimer's Association, respite care services, and dedicated caregiver counseling should be actively offered to every family.

Safety planning should begin at the MCI stage rather than after crises have occurred. Essential components include driving assessment and development of a cessation plan, evaluation of medication management abilities, implementation of wandering precautions (GPS trackers, door alarms, enrollment in the MedicAlert and Alzheimer's Association Safe Return program), firearm removal from the home, and protection against financial exploitation.

Staging and Prognosis

Average survival from the time of Alzheimer disease diagnosis ranges from 4 to 8 years, with a wider range of 3 to 20 years depending on age at onset, comorbidities, and the speed of disease progression. The trajectory of functional decline follows a predictable pattern in which instrumental activities of daily living are lost first (financial management, medication management, and driving) followed by basic activities of daily living (bathing, dressing, toileting, and feeding, in that approximate order).

Advanced Alzheimer disease is characterized by loss of ambulation, dysphagia, urinary and fecal incontinence, and minimal verbal output. The Functional Assessment Staging Test (FAST) developed by Reisberg provides detailed staging, with stage 7 representing severe dementia. Reaching FAST stage 7C, defined by loss of ambulation, is associated with a median survival of approximately six months and establishes eligibility for hospice referral. The principal causes of death in advanced Alzheimer disease include aspiration pneumonia, sepsis, cardiovascular events, and cachexia.

Key Clinical Pearls

• Always obtain collateral history from an informant — patients with AD frequently underreport symptoms due to anosognosia
• Blood-based biomarkers (p-tau217) are transforming AD diagnosis — they can now confirm amyloid pathology without PET or lumbar puncture
• Anti-amyloid therapies (lecanemab, donanemab) offer the first disease-modifying treatments but are limited to early-stage AD with confirmed amyloid — early diagnosis is now clinically actionable
• ARIA monitoring is mandatory with anti-amyloid therapy — APOE4 homozygotes require careful risk-benefit discussion given 35% ARIA-E risk
• Cholinesterase inhibitors and memantine remain the backbone of symptomatic treatment across all stages — their benefit is most apparent when they are stopped
• Caregiver health predicts patient outcomes — always assess caregiver burden and connect to support resources
• Safety planning (driving, firearms, wandering, finances) should begin at the MCI stage, not after crises occur

References

1. van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer's disease. N Engl J Med. 2023;388(1):9-21.
2. Sims JR, Zimmer JA, Evans CD, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330(6):512-527.
3. Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14(4):535-562.
4. Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396(10248):413-446.
5. Palmqvist S, Janelidze S, Quiroz YT, et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2020;324(8):772-781.

Read this lecture as Markdown